Vernalis, PhoreMost announce drug discovery collaboration for novel oncology target

This article was originally published here

PhoreMost has identified and validated the target using its next-generation SITESEEKER phenotypic screening technology. Ligand will now apply its Vernalis Design Platform (VDP) to design small molecule inhibitors

The post Vernalis, PhoreMost announce drug discovery collaboration for novel oncology target appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply